← Patent-cliff monitor small molecule BLUJEPA GEPOTIDACIN MESYLATE
Loss of exclusivity December 2042 latest FDA-listed patent expiry
Drug detail Brand name BLUJEPA Active ingredient GEPOTIDACIN MESYLATE Strength EQ 750MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2025 Marketing status RX
Listed patents Patent Expires Type 12528809 December 2042 substance, product 10702521 August 2035 use U-4361 11229646 August 2035 use U-4361 8389524 February 2029 substance, product
Regulatory exclusivity Code Expires GAIN March 2035 NCE March 2030 I-978 December 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.